MX2014002223A - Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. - Google Patents

Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.

Info

Publication number
MX2014002223A
MX2014002223A MX2014002223A MX2014002223A MX2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A MX 2014002223 A MX2014002223 A MX 2014002223A
Authority
MX
Mexico
Prior art keywords
pathogen
immune system
cells
immune
immunological memory
Prior art date
Application number
MX2014002223A
Other languages
Spanish (es)
Inventor
Carlos Alvirde Sucilla
Original Assignee
Carlos Alvirde Sucilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlos Alvirde Sucilla filed Critical Carlos Alvirde Sucilla
Priority to MX2014002223A priority Critical patent/MX2014002223A/en
Publication of MX2014002223A publication Critical patent/MX2014002223A/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. The adaptive immune system allows a higher immune response to be obtained, as well as the establishment of the immunological memory, where each pathogen is remembered by an antigen characteristic of this pathogen in particular. This response generates immunological memory producing, in most cases, permanent immunity against the disease. The cells of the adaptive immune system are a special class of leukocytes, known as lymphocytes. The B and T cells are the main class of lymphocytes and result from pluripotent hematopoietic stem cells. The B and T cells contain receptor molecules that recognize specific targets. The T cells recognize a strange target, as a pathogen, manly after the antigens (small fragments of pathogens) have been processed and presented in com bination with an own receptor. Included is a normal saline solution of 80% to 90% exclusively for being used in tissue culturing, which is sterilized by the membrane and free of pyrogens. All these components are mixed in an amber glass container of 100ml, with 50 ml of solution under a range of 40 ml to 60 ml.

Description

METHOD FOR THE TREATMENT OF SELF-IMMUNE DISEASES TO CREATE ANTI-ANTIBODIES AND STRENGTHEN THE IMMUNE SYSTEM BACKGROUND In the medical field, it has been determined that it is logical to take advantage of the patient's own blood to use the auto antibodies as true antigens and thus stimulate the immune system to produce normal antibodies that block and destroy the auto antibodies.
The soluble antibodies are secreted by an activated B lymphocyte ^ its plasma cell form) to bind to foreign substances and signal them for destruction by the rest of the immune system.
They could also be called free antibodies to autoimmune diseases are caused by an antibody that by a defect of the immune system is released from the cell and attacks the immune system itself should defend Specific for Pénfigo vulgar.Miastenia gravis organ. Thyroiditis of Hashlmoto.MIxedema prlmario.Silver disease Miller-Fisher syndrome. Myasthenia of Lambert-Eaton. Sympathetic ophthalmia. Neuropatiasüveitis. asthma. Primary biliary cirrhosis. Sclerosing cholangitis primary autoimmune hepatitis, celiac disease, gastric atrophy, pernicious anemia, Diabetes mellitus type 1, Diabetes mellitus type 2, Crohn's disease, Ulcerative colitis, Goodpasture syndrome.
Multiorganic or systematic Multiple sclerosis, Devic's disease, Amyotrophic lateral sclerosis, PsoriasisVitiligo, Wegener's granulomatosis, Beh et's disease, Systemic vasculitis, Chronic fatigue syndrome, Fibromyalgia, Multiple sclerosis Devic's disease, Amyotrophic lateral sclerosis, Psoriasis, Vitiligo granulomatosis Wegener, Behget's disease, Systemic vasculitis, Chronic fatigue syndrome, Fibromyalgia. Immune compromised patients (low immune system) in patients with diseases such as cancer, human papilloma virus, C hepatitus, and HIV virus (carriers) b or (AIDS) Acquired Immune Deficiency Syndrome.
Traditionally autoimmune diseases are treated with corticosteroids are hormones of the group of steroids (produced by the cortex of the adrenal glands) and their derivatives Corticosteroids are implicated in a variety of physiological mechanisms, including those that regulate inflammation, the immune system, carbohydrate metabolism, protein catabolism, plasma electrolyte levels and, finally, those that characterize the response to stress DESCRIPTION It is possible to take advantage of the patient's own blood to use the auto-antibodies as true antigens and thus stimulate their Immune System to produce normal antibodies that block and destroy the auto-antibodies. 5 to 6 milliliters of intravenous blood are removed in a range of 1 to 10. This blood is inoculated into a tissue culture substance in a 100-milliliter flask with 50 milliliters of normal saline, 0.85% membrane-sterilized, for exclusive use for tissue culture.
Immediate agitation or suction, (manual or machine) to break the red blood cells, a procedure known as hematolysis, is performed at more than 1000 revolutions per minute, the erythrocytes are lysed and the antigens are released on the surface Thermal shock is performed at 4 ° C for a time understood depending on the type of disease of the patient, sedimented for 24 hours. Before the first application An autovaccine is obtained with its own antigens, now transformed into cold antibodies, for all diseases of auto-immune origin and not only patients receiving immune cell therapy and who are healthy, significantly improve their immune system.
With 6 milliliters of blood, 52 doses can be obtained so that later they can be administered in the indicated doses, depending on the specific disease. It can be applied 2 or 3 times a day.
It is wicked and does not produce side effects so it is not aggressive to the patient.
They can be applied up to 15 to those without collateral or secondary effects. This solution is re injected to the patient in specific doses and periods, in the abdomen exclusively with insulin syringe, the antigens to be released and cultured transform the molecule into true ANTI-ANTIBODIES The anti-antibodies by their transformation and molecular weight have the ability to adapt to the immunological memory, this produces a response that improves the immune system and strengthens B and T lymphocytes The antibody that became self-antigen, now transformed into anti-antibody is the most applicable method to generate auto-immune memory.
At the end of the first treatment of 52 doses depending on the duration (may be 28 days) The patient will go to perform the second to a, blood for the proportion of 2 doses until the doctor determines the time and duration of it, the treatment of each patient in his own home in refrigeration at 6 degrees Celsius or less without reaching the freezing point.
Symptoms and Side Effects There are no reports of side effects since it is the patient's own blood, there is a reduction in the consumption of control medications, as well as greater energy thanks to the strengthening of B and T lymphocytes.
Weight reduction is achieved as it acts as a detoxifier of the immune system in addition to significant reduction of common symptoms of the disease.

Claims (4)

CLAIMS Having sufficiently described my invention, I consider as a novelty therefore I claim as my exclusive property, what is contained in the following clauses:
1. A method for the treatment of auto-immune diseases to create anti-bodies and strengthen the immune system, by obtaining antigens upon release and cultivation transform the molecule into true ANTI-ANTIBODIES comprising the following steps:
2. Claim 1 and the anti-antibodies by their transformation and molecular weight have the ability to adapt to the immunological memory.
3. Claim 1 strengthens B and T lymphocytes.
4. Claim 1, the antibody that was transformed into autoantigen, now transformed into anti-antibody is the most applicable method for generating auto-immune memory.
MX2014002223A 2014-02-25 2014-02-25 Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system. MX2014002223A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2014002223A MX2014002223A (en) 2014-02-25 2014-02-25 Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2014002223A MX2014002223A (en) 2014-02-25 2014-02-25 Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.

Publications (1)

Publication Number Publication Date
MX2014002223A true MX2014002223A (en) 2015-08-25

Family

ID=54598933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002223A MX2014002223A (en) 2014-02-25 2014-02-25 Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.

Country Status (1)

Country Link
MX (1) MX2014002223A (en)

Similar Documents

Publication Publication Date Title
Zhang et al. GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response
CN106589133A (en) Preparation and applications of liver-cancer-specific CTL cells induced by new enhanced antigen combined polypeptide
Schepici et al. Regenerative effects of exosomes-derived MSCs: an overview on spinal cord injury experimental studies
CN107557333A (en) A kind of neoantigen for cell therapy is in the preparation method of delivery cell
Han et al. The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation
MX2014002223A (en) Method for treating auto-immune diseases for creating anti-bodies and strengthening the immune system.
EP3148574B1 (en) Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
JP2019508458A5 (en)
Qi et al. P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity
Siegel et al. Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma
EP4306128A3 (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
CN107028982A (en) Human plactnta hepatitis B specific immune activity polypeptide
US20160340650A1 (en) Blood derived immune stimulatory compositions
Martínez-Alcantar et al. Anterior chamber associated immune deviation to cytosolic neural antigens avoids self-reactivity after optic nerve injury and polarizes the retinal environment to an anti-inflammatory profile
Wu et al. Effects of bone marrow mesenchymal stem cells on the cardiac function and immune system of mice with endotoxemia
Kim et al. Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus
WO2017142014A1 (en) Drug for inflammatory disease
Barabas et al. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique
TW201420130A (en) Liquid agent containing dissolved carbon dioxide and administrating method thereof
Sung et al. Polysaccharide extracted from Sargassum fulvellum leads to macrophage activation and Th1 polarization in splenocytes
RU2585097C1 (en) Method of treating chronic pancreatitis
RU2013110503A (en) METHOD AND DEVICE FOR TREATING DISORDERS RELATED TO THE CHOLESTEROL LEVEL IN BLOOD
RU2755638C2 (en) Method for increasing antitumour resistance, antioxidant and immunostimulating effects on the body
Vázquez et al. New therapeutic alternatives for severe sepsis in the critical patient. A review
RU2682320C1 (en) Means for the prevention of viral infections